Transgenic Mouse Models of Alzheimer's Disease
Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine · 2010-01 · 77 (1) · 69-81
DOI: 10.1002/msj.20159 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine, online erschienen am 25.01.2010. Verfasst von Gregory A Elder und 2 weiteren Autor:innen. Beteiligte Einrichtung: Neurology Service, James J. Peters Department of Veterans Affairs Medical Center, Bronx, NY, USA. gregory.elder@mssm.edu. Hauptthemen laut MEDLINE: Disease Models, Animal, Mice, Transgenic. Die Arbeit wurde bisher 284-mal zitiert (Crossref) und nennt 103 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: BLRD VA, NIA NIH HHS.
Themen: Demenz
Abstract (Originalsprache)
Alzheimer's disease is the most common cause of senile dementia in the United States and Europe. At present, there is no effective treatment. Given the disease's prevalence and poor prognosis, the development of animal models has been a high research priority. Transgenic modeling has been pursued on the basis of the amyloid hypothesis and has taken advantage of mutations in the amyloid precursor protein and the presenilins that cause familial forms of Alzheimer's disease. Modeling has been most aggressively pursued in mice, for which the techniques of genetic modification are well developed. Transgenic mouse models now exist that mimic a range of Alzheimer's disease–related pathologies. Although none of the models fully replicates the human disease, the models have contributed significant insights into the pathophysiology of β‐amyloid toxicity, particularly with respect to the effects of different β‐amyloid species and the possible pathogenic role of β‐amyloid oligomers. They have also been widely used in the preclinical testing of potential therapeutic modalities and have played a pivotal role in the development of immunotherapies for Alzheimer's disease that are currently in clinical trials. These models will, without a doubt, continue to play central roles in preclinical testing and be used as tools for developing insights into the biological basis of Alzheimer's disease. Mt Sinai J Med 77:69&–81, 2010. © 2010 Mount Sinai School of Medicine
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Neurology Service, James J. Peters Department of Veterans Affairs Medical Center, Bronx, NY, USA. gregory.elder@mssm.edu
Förderung
- BLRD VA
- NIA NIH HHS
Zitieren
APA
Elder, G. A., Gama Sosa, M. A., & De Gasperi, R. (2010). Transgenic Mouse Models of Alzheimer's Disease. Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine, 77(1), 69-81. https://doi.org/10.1002/msj.20159
Vancouver
Elder GA, Gama Sosa MA, De Gasperi R. Transgenic Mouse Models of Alzheimer's Disease. Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine. 2010;77(1):69-81. doi:10.1002/msj.20159
BibTeX
@article{Elder2010,
author = {Elder, Gregory A and Gama Sosa, Miguel A and De Gasperi, Rita},
title = {Transgenic Mouse Models of Alzheimer's Disease},
journal = {Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine},
year = {2010},
volume = {77},
number = {1},
pages = {69--81},
doi = {10.1002/msj.20159}
}
EUVIMED